



Informazioni personali

Nome / Cognome

SEBASTIANO FILETTI

Dipartimento

Medicina Interna e Specialità Mediche
Università di Roma- Azienda Policlinico Umberto I- Viale del Policlinico,155 00161 Roma

Settore Scientifico-Disciplinare MED/09 Medicina Interna

Indirizzo

Azienda Ospedaliera Universitaria- Policlinico Umberto I
Viale del Policlinico, 155 - 00161 Roma

E-mail sebastiano.filetti@uniroma1.it
s.filetti@policlinicoumberto1.it

Codice Fiscale FLTST49E13C351G

Telefono 06 4997.5130

Fax 06 4997.8372

Attuale Posizione

Professore Ordinario di Medicina Interna presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Roma "Sapienza

Direttore DAI di Medicina Interna e Specialità Mediche. Azienda ospedaliero-universitaria policlinico Umberto I

Dirigente Medico di II livello responsabile U.O.C. di Medicina Interna e Malattie Metaboliche – Azienda Policlinico Umberto I - Roma

Delegato del Rettore per i “Rapporti internazionali area sanitaria”- biennio 2018-2020

Editor in Chief “Endocrine-Springer dal 2018-

Preside della Facoltà di Medicina e Odontoiatria dell'Università degli Studi di Roma "Sapienza"2015 – 2018“

Componente Commissione Tecnico-scientifica dell'AIFA (Agenzia Italiana del Farmaco), 2015-2018

Coordinatore Dottorato di Ricerca “Tecnologie biomediche in Medicina Clinica” (cod. 11124)” Università degli Studi di Roma "Sapienza" dal 2007

Coordinatore della Scuola di Specializzazione in Medicina Interna dell'Università degli Studi di Roma "Sapienza" dal 2009 a ottobre 2017

Coordinatore Tronco comune Scuole di Specializzazione di Area Medica “Sapienza” Università di Roma

Docente presso le Scuole di Specializzazione dell'Università degli Studi di Roma "Sapienza": Scuola di Specializzazione in Medicina Interna; Scuola di Specializzazione in Endocrinologia e Malattie del Ricambio; Scuola di Specializzazione in Gastroenterologia dal 2007-2015

Formazione

Professore Ordinario di Medicina Interna, Università di Roma "Sapienza" dal 2001 ad oggi
Presidente del Corso di Laurea Magistrale in Medicina e Chirurgia "A", Sapienza Università di Roma dal 2010 a Novembre 2015
Professore Ordinario di Medicina Interna, Università di Catanzaro dal 1997 - 2001
Professore Ordinario di Endocrinologia, Università di Catanzaro, 1994-97
Professore Associato di Endocrinologia, Università di Reggio Calabria, Catanzaro 1987-1993
Ricercatore in Patologia Medica, Università di Catania, 1980-1987
Specializzazione in Endocrinologia, Catania, luglio 1975
Laurea in Medicina e Chirurgia, Catania, 30 novembre 1973

Madrelingua

Italiano

Other language(s)

Inglese
Francese

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
C1	C1	C1	C1	C1
C1	C1	C1	C1	C1

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Premi:

1979 Grant Fullbright-Hays
1979 Premio della Società Italiana di Diabetologia
1984 Premio della Società Italiana di Endocrinologia
1997 Premio della Società Italiana di Endocrinologia

Società scientifiche:

Endocrine Society, American Thyroid Association, American Diabetes Association, Società di Medicina Interna, Società Italiana di Endocrinologia, Società Italiana di Diabetologia,

Altre capacità e competenze

Editor in Chief "ENDOCRINE" Springer dal 2018-
Associate Editor della rivista "Endocrine", Springer, N.Y. dal 2014-2018
Associate Editor di Orphanet Journal of Rare Diseases dal 2009-2017
Consiglio Scientifico dell'EFEC (Ecole de Formation Européenne en Cancérologie) dal 2003-2012
Editorial Board di "The Journal of Clinical Endocrinology and Metabolism" dal 2004-2009

Esperienze in laboratori esteri:

1 anno a Bruxelles (Belgio), 1 anno a Londra (Gran Bretagna), 5 anni presso l'Università della California, San Francisco (USA).
In atto collabora con il Department of Endocrine Neoplasia & Hormonal Disorders, M.D. Anderson, University of Texas, Houston, USA e con L'Istituto Tumori Gustave-Roussy, Parigi
esperienza di ricerca in metabolismo ed endocrinologia cellulare/molecolare e clinica.

Il Professor Sebastiano Filetti ha maturato esperienza clinica in qualità di responsabile di U.O.C. di Medicina Interna dal 1994 ad oggi. Ha partecipato a numerosi trials clinici, ed è stato responsabile di ricerca di circa 40 studi clinici negli ultimi anni. (Phase II, Phase III) fino al 30/08/2015.

Brief Summary of Relevant Clinical Research Experience:
06 trials in the cardiovascular field 10 trials in metabolism/dyslipidemia 05 endocrine oncology and thyroid cancer 18 trials in Type II Diabetes GCP training at investigators meeting for these studies

Sperimentazioni Cliniche:

Amgen. ClinicalTrials.gov: NCT00121628	2004	2005	A Phase 2, Open-Label Study of AMG 706 to Treat Subjects with Locally Advanced or Metastatic Thyroid Cancer who are not Candidate for Radioactive Iodine Therapy
AstraZeneca. ClinicalTrials.gov: NCT0041076. Study ID Number: D4200C00058	2006	2015*	An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Novo Nordisk. ClinicalTrials.gov: NCT00700817. Study ID Number: NN2211-1860	2008	2009	The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes. A 26-week, Randomised, Open-label, Active Comparator, Three-armed, Parallel-group, Multi-centre, Multinational Trial With a 52-week Extension
AstraZeneca. ClinicalTrials.gov: NCT00660907. Study ID Number: D1690C00004	2008	2010	A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III Study With a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination With Metformin Compared With Sulphonylurea in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone
Bayer. ClinicalTrials.gov: NCT00501059. Study ID Number: 12198	2008	2015*	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Novartis. ClinicalTrials.gov: NCT00549757. Study ID Number: CSPP100E2337	2008	2015*	A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality
Merck Sharp & Dohme. ClinicalTrials.gov: NCT00722371. Study ID Number: 0431-102	2009	2010	A Multicenter, Randomized, Double-Blind Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Novartis. ClinicalTrials.gov: NCT00860288. Study ID Number: CLAF237B2224	2009	2011	A Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Long-Term Safety of Vildagliptin Modified Release (MR) as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Bayer. Chairman Data Monitoring. ClinicalTrials.gov: NCT00984282. Study ID Number: 14295	2009	2013	A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
EISAI. ClinicalTrials.gov: NCT00784303. Study ID Number: E7080-G000-201	2009	2014	A Phase II, Multicenter, Open Label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

Exelixis. ClinicalTrials.gov: NCT00704730. Study ID Number: XL184-301	2009	2014	An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 versus Placebo in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Novo Nordisk. ClinicalTrials.gov: NCT00972283. Study ID Number: NN1250-3582	2010	2011	NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment (BEGIN™: BB)
Novo Nordisk. ClinicalTrials.gov: NCT00972283. Study ID Number: NN1250-3667	2011	2011	NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)
AstraZeneca/Eli Lilly. ClinicalTrials.gov: NCT01060059. Study ID Number: H8O-IT-B014	2010	2012	EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients With Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment
EISAI. ClinicalTrials.gov: NCT01321554. Study ID Number: E7080-G000-303	2010	2015*	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer
Novo Nordisk. ClinicalTrials.gov: NCT01179048. Study ID Number: EX2211-3748	2010	2015*	A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
AstraZeneca. ClinicalTrials.gov: NCT01298323. Study ID Number: D4200C00088	2011	2014	A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib
Medtronic. ClinicalTrials.gov: NCT01182493. Study ID Number: EUR05/CEP234	2011	2015*	OpT2mise Glucose Control in Type 2 DM With Insulin Pump Therapy
Merck Sharp & Dohme. ClinicalTrials.gov: NCT01296412. Study ID Number: 0431-403	2011	2015*	A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy
Merck Sharp & Dohme. ClinicalTrials.gov: NCT01462266. Study ID Number: 0431-260	2012	2015*	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin
Novartis. ClinicalTrials.gov: NCT01528254. Study ID Number: CLAF237A23156	2012	2015*	A 5-year Study to Compare the Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Novo Nordisk. ClinicalTrials.gov: NCT01664247. Study ID Number: NN1250-3944	2012	2015*	The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
AstraZeneca. ClinicalTrials.gov: NCT01496313. Study ID Number: D4200C00097	2012	2015	An International, Randomised, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease
Merck Sharp & Dohme. ClinicalTrials.gov: NCT01703208. Study ID Number: 3102-018	2013	2015*	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus

AstraZeneca. ClinicalTrials.gov: NCT01876784. Study ID Number: D4203C00011	2013	2015*	A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
AstraZeneca. ClinicalTrials.gov: NCT01843062. Study ID Number: D1532C00065	2013	2015*	A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer
Novo Nordisk. ClinicalTrials.gov: NCT01885208. Study ID Number: NN9535-3624	2013	2015*	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)
Novo Nordisk. ClinicalTrials.gov: NCT01923181. Study ID Number: NN9924-3790	2013	2014	Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk. ClinicalTrials.gov: NCT01959529. Study ID Number: EX1250-4080	2014	2015*	A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

EXPERIENCE IN SELECTED CLINICAL TRIALS

*From September 1st, 2015, Sebastiano Filetti left the position of Principal Investigator of these Clinical Trials due to a concomitant appointment as a member of the AIFA (Italian Drugs Agency) Technical-Scientific Committee.

Please note: all these Clinical Trials included a GCP training

*

BOOK CHAPTERS:

1. **“Non toxic goiter and thyroid neoplasia”** pubblicato nel volume **Williams Textbook of Endocrinology** – 13th Edition 2015, Editors: Larsen, Kronenberg, Melmed, Polonsky, Saunders Publisher
2. Sebastiano Filetti, Cosimo Durante, Clark/Duh **Radioactive Iodine Therapy: Mechanisms and Indications** : Endocrine Surgery textbook JP Brothers Medical Publishers, 2015
3. Maria Chiara Zatelli, Efsio Puxeddu, Elisa Menicali, Ettore degli Uberti, and Sebastiano Filetti **Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies** Springer International Publishing Switzerland 2015 C.P. Lombardi, R. Bellantone (eds.), Minimally Invasive Therapies for Endocrine Neck Diseases
4. S. Filetti, R. Michael Tuttle, Steven I. Sherman **Medical Management of differentiated epithelial cell thyroid cancer** pubblicato nel volume “Werner & Ingbar’s the Thyroid, a Fundamental and Clinical Text” Editors: Braverman L, Cooper DS. , 10th Edition. Philadelphia, Lippincott Williams & Wilkins, 2013. Chapter 50E, pag. 725-743.
5. **“Non toxic goiter and thyroid neoplasia”** pubblicato nel volume **Williams Textbook of Endocrinology** – 12th Edition 2011, chapter 14, Editors: Larsen, Kronenberg, Melmed, Polonsky, Saunders Publisher
6. **“Carcinoma midollare della tiroide: genetica e diagnostica molecolare”** pubblicato nel volume **LaTiroide, Fisiopatologia, diagnostica molecolare – clinica e terapia**, 2004, Editor Andreoli, Il Pensiero Scientifico Publisher
7. **“L’Algoritmo diagnostico”** pubblicato nel volume **Tiroide, diagnostica per immagini e approccio clinico ragionato**, Editors: Lagalla, Attard, Latteri, Midiri, Idelson-Gnocchi Publisher 2004
8. **“Multiple endocrine neoplasia 2”** pubblicato nel volume **Update in Neuroendocrinology**, Editors: Baldelli, Casanueva, Tamburrano, Pubblicazioni Medico Scientifiche Publisher 2004
9. **“Meccanismo di secrezione, dell’azione ormonale e della risposta tissutale”** pubblicato nel volume **Endocrinologia**, 1992 Editors: Pinchera, Fenzi, UTET Publisher
10. **“ Molecular Markers in Thyroid Fine-Needle Aspiration Biopsies”** pubblicato nel volume “Minimally Invasive Therapies for Endocrine Neck Diseases”, Editors: Lombardi CP, Bellantone R. Springer 2016, 37-51

PROCEEDING MEETINGS OF REPORTS:

1. Arturi F, Chiefari E, Scarpelli D, Russo D, **Filetti S**

"Strumenti di diagnosi molecolare in endocrinologia" pubblicato nel volume Aspetti di diagnosi molecolare e terapia genica delle neoplasie endocrine, (Atti del convegno – Padova, 29 ottobre 1999) Editors: Barzon, Bonaguro, Boscaro, Palù 2000 -Time Science Publisher

2. Russo D, Arturi F, Ferretti E, **Filetti S**

"Iodine transport in normal and neoplastic thyroid cells" pubblicato nel volume "Signal transduction and neoplastic transformation in endocrine systems: molecular mechanisms and clinical aspects" (Atti del Convegno presso l'Accademia Nazionale dei Lincei 5-6/04/2002), Bardi Editore Publisher

3. Irace C, Maranghi M, **Filetti S**

"Ipotiroidismo, lipidi e rischio cardiovascolare" pubblicato nel volume Ipotiroidismi: dalla fisiopatologia al trattamento, (Atti del convegno – Vicenza, 27 maggio 2005) Editors: Basso A., Giochetti M. - 2006

4. Durante C, Romagnoli E, Maranghi M, D'Aloiso L, Minisola S, D'Erasmo E, **Filetti S**

Hyperparathyroidism in multiple endocrine neoplasia type IIA
Clinical Cases in Mineral and Bone Metabolism 2006, 3(2): 162 – 166

5. **Filetti S**, Durante C, Maranghi M

A genetic based disease management in inherited cancer syndromes: the multiple endocrine neoplasia model.
Supportive & Palliative Cancer Care, Suppl. 2006, 2: 13-16

R

PEER-REVIEWED ARTICLES

ARTICLES N° = 284

H INDEX = 59 (ISI WEB OF SCIENCE) Times cited : 12.871

1. Filetti S. Quo vadis Endocrine-Part II.Endocrine. 2019 Jan;63(1):1-2. doi: 10.1007/s12020-018-1828-5. No abstract available. PMID:30591986;
2. Raparelli V, Proietti M, Lenzi A, Basili S; EVA Collaborators. Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design.J Cardiovasc Transl Res. 2018 Dec 3. doi: 10.1007/s12265-018-9846-5. [Epub ahead of print] PMID:30511337;
3. Pecce V, Sponziello M, Damante G, Rosignolo F, Durante C, Lamartina L, Grani G, Russo D, di Gioia CR, Filetti S, Verrienti A. A synonymous RET substitution enhances the oncogenic effect of an in-cis missense mutation by increasing constitutive splicing efficiency. PLoS Genet. 2018 Oct 15;14(10):e1007678. doi: 10.1371/journal.pgen.1007678. eCollection 2018 Oct. PMID:30321177;
4. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS.J Clin Endocrinol Metab. 2019 Jan 1;104(1):95-102. doi: 10.1210/jc.2018-01674. PMID:30299457;

5. Grani G, Lamartina L, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, **Filetti S**, Durante C. Sonographically Estimated Risks of Malignancy for Thyroid Nodules Computed with Five Standard Classification Systems: Changes over Time and Their Relation to Malignancy. *Thyroid*. 2018 Sep;28(9):1190-1197. doi: 10.1089/thy.2018.0178. PMID:30105949
6. Lamartina L, Grani G, Durante C, Borget I, **Filetti S**, Schlumberger M. Follow-up of differentiated thyroid cancer - what should (and what should not) be done. *Nat Rev Endocrinol*. 2018 Sep;14(9):538-551. doi: 10.1038/s41574-018-0068-3. Review. PMID:30069030
7. Sponziello M, Silvestri G, Verrienti A, Perna A, Rosignolo F, Brunelli C, Pecce V, Rossi ED, Lombardi CP, Durante C, **Filetti S**, Fadda G. A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma. *Endocrine*. 2018 Apr 26. doi: 10.1007/s12020-018-1611-7.
8. Lepore G, Bonfanti R, Bozzetto L, Di Blasi V, Girelli A, Grassi G, Iafusco D, Laviola L, Rabbone I, Schiaffini R, Bruttomesso D; Italian Study Group on the Diffusion of CSII. Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. *Nutr Metab Cardiovasc Dis*. 2018 Apr;28(4):335-342. doi: 10.1016/j.numecd.2017.12.001. PMID:29428572.
9. Lamartina L, Grani G, Durante C, **Filetti S**. Recent advances in managing differentiated thyroid cancer. *F1000Res*. 2018 Jan 18;7:86. doi: 10.12688/f1000research.12811.1. eCollection 2018. Review.PMID:29399330.
10. Allegri L, Mio C, Russo D, Filetti S, Baldan F. Effects of HuR downregulation on anaplastic thyroid cancer cells. *Oncol Lett*. 2018 Jan;15(1):575-579. doi: 10.3892/ol.2017.7289. Epub 2017 Oct 30.PMID:29285201.
11. Rosignolo F, Sponziello M, Giacomelli L, Russo D, Pecce V, Biffoni M, Bellantone R, Lombardi CP, Lamartina L, Grani G, Durante C, **Filetti S**, Verrienti A Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up. *J Endocr Soc*. 2017 Jan 12;1(1):3-13. doi: 10.1210/js.2016-1032. eCollection 2017 Jan 1.PMID:29264441
12. Mio C, Conzatti K, Baldan F, Allegri L, Sponziello M, Rosignolo F, Russo D, **Filetti S**, Damante G. BET bromodomain inhibitor JQ1 modulates microRNA expression in thyroid cancer cells.*Oncol Rep*. 2018 Feb;39(2):582-588. doi: 10.3892/or.2017.6152. Epub 2017 Dec 12. PMID:29251329
13. Sponziello M, Benvenuti S, Gentile A, Pecce V, Rosignolo F, Virzi AR, Milan M, Comoglio PM, Londin E, Fortina P, Barnabei A, Appetecchia M, Marandino F, Russo D, **Filetti S**, Durante C, Verrienti A. Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.*Hum Mutat*. 2017 Dec 8. doi: 10.1002/humu.23378. [Epub ahead of print] PMID:29219214
14. Allegri L, Rosignolo F, Mio C, **Filetti S**, Baldan F, Damante G. Effects of nutraceuticals on anaplastic thyroid cancer cells. *J Cancer Res Clin Oncol*. 2017 Dec 2. doi: 10.1007/s00432-017-2555-7. [Epub ahead of print] PMID:29197967
15. Lamartina L, Grani G, Arvat E, Nervo A, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Massa M, Bellantone R, Pontecorvi A, Montesano T, Pagano L, Daniele L, Fugazzola L, Ceresini G, Bruno R, Rossetto R, Tumino S, Centanni M, Meringolo D, Castagna MG, Salvatore D, Nicolucci A, Lucisano G, **Filetti S**, Durante C. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. *Endocr Relat Cancer*. 2017 Nov 30. pii: ERC-17-0453. doi: 10.1530/ERC-17-0453. [Epub ahead of print] PMID:29192093
16. Mazziotti G, Formenti AM, Panarotto MB, Arvat E, Chiti A, Cuocolo A, Dottorini ME, Durante C, Agate L, **Filetti S**, Felicetti F, Filice A, Pace L, Pellegrino T, Rodari M, Salvatori M, Tranfaglia C, Versari A, Viola D, Frara S, Berruti A, Giustina A, Giubbini R. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. *Endocrine*. 2017 Nov 6. doi: 10.1007/s12020-017-1455-6. [Epub ahead of print] PMID:29110129
17. Grani G, Lamartina L, Durante C, **Filetti S**, Cooper DS. Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment, and clinical management. *Lancet Diabetes Endocrinol*. 2017 Oct 25. pii: S2213-8587(17)30325-X. doi: 10.1016/S2213-8587(17)30325-X. [Epub ahead of print] Review. PMID:29102432
18. Lamartina L, Durante C, Lucisano G, Grani G, Bellantone RA, Lombardi CP, Pontecorvi A, Arvat E, Felicetti F, Zatelli MC, Rossi R, Puxeddu E, Morelli S, Torlontano M, Crocetti U, Montesano T, Giubbini R, Orlandi F, Aimaretti G, Monzani F, Attard M, Francese C, Antonelli A, Limone PP, Rossetto R, Fugazzola L, Meringolo D, Bruno R, Tumino S, Ceresini G, Centanni M, Monti S, Salvatore D, Mian C, Spiazzi G, Persani L, Barbaro D, Nicolucci A, Filetti S. Are evidence-based guidelines reflected in clinical practice? An analysis of prospectively collected data of the Italian Thyroid Cancer Observatory (ITCO#1).*Thyroid*. 2017 Oct 12. doi: 10.1089/thy.2017.0299. PMID:29020892.
19. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes.*N Engl J Med*. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. PMID:28854085.
20. Grani G, Bruno R, Lucisano G, Costante G, Meringolo D, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Cooper DS, Filetti S, Durante C. Temporal Changes in Thyroid Nodule Volume: Lack of Effect on Paranodular Thyroid Tissue Volume. *Thyroid*. 2017 Sep 14. doi: 10.1089/thy.2017.0201. PMID:28806880.
21. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. PMID:28605603.
22. Rosignolo F, Memeo L, Monzani F, Colarossi C, Pecce V, Verrienti A, Durante C, Grani G, Lamartina L, Forte S, Martinetti D, Giuffrida D, Russo D, Basolo F, Filetti S, Sponziello M. MicroRNA-based molecular classification of papillary thyroid carcinoma. *Int J Oncol*. 2017 May;50(5):1767-1777. doi: 10.3892/ijo.2017.3960. Epub 2017 Apr 7. PMID:28393181.
23. Maggisano V, Celano M, Lombardo GE, Lepore SM, Sponziello M, Rosignolo F, Verrienti A, Baldan F, Puxeddu E, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. *Mol Cell Endocrinol*. 2017 Mar 10. pii: S0303-7207(17)30176-4. doi: 10.1016/j.mce.2017.03.007 PMID:28288903.
24. Giannetta E, Isidori AM, Durante C, Di Gioia C, Longo F, Tombolini V, Bulzonetti N, Graziadio C, Pofi R, Gianfrilli D, Verrienti A, Carletti R, Filetti S, Lenzi A, Baroli A. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. *Medicine (Baltimore)*. 2017 Feb;96(6):e5621. doi: 10.1097/MD.0000000000005621.PMID:28178124
25. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical

- incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine*. 2016 Nov;54(2):467-475. PMID: 26668060.
26. Grani G, Lamartina L, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, Durante C, Cantisani V. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules. *Endocrine*. 2016 Oct 31. [Epub ahead of print] PMID:27804016.
 27. Essig GF Jr, Porter K, Schneider D, Arpaia D, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas LH, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study. *Thyroid*. 2016 Nov;26(11):1563-1572. PMID:27604949.
 28. Cohen O, Filetti S, Castañeda J, Maranghi M, Glandt M. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump. *Diabetes Care*. 2016 Aug;39 Suppl 2:S180-6. doi: 10.2337/dcS15-3029.
 29. Verrienti A, Tallini G, Colato C, Boichard A, Checquolo S, Pecce V, Sponziello M, Rosignolo F, De Biase D, Rhoden K, Casadei GP, Russo D, Visani M, Acquaviva G, Ferdeghini M, Filetti S, Durante C. RET mutation and increased angiogenesis in medullary thyroid carcinomas. *Endocr Relat Cancer*. 2016 Jul 8. pii: ERC-16-0132. [Epub ahead of print].
 30. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
 31. Lamartina L, Deandrei D, Durante C, Filetti S. ENDOCRINE TUMOURS: Imaging in the follow up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. *Eur J Endocrinol*. 2016 Jun 1. pii: EJE-16-0088.
 32. Rosignolo F, Sponziello M, Durante C, Puppini C, Mio C, Baldan F, Di Loreto C, Russo D, Filetti S, Damante G. Expression of PAX8 Target Genes in Papillary Thyroid Carcinoma. *PLoS One*. 2016 Jun 1;11(6):e0156658. doi: 10.1371/journal.pone.0156658. eCollection 2016.
 33. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. *J Clin Endocrinol Metab*. 2016 May 17;jc20161440.
 34. Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, Russo D, Bulotta S. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Mol Cell Endocrinol*. 2016 Aug 15;431:123-32. doi: 10.1016/j.mce.2016.05.007. Epub 2016 May 10.
 35. Filetti S, Ladenson PW, Biffoni M, D'Ambrosio MG, Giacomelli L, Lopatriello S. The true cost of thyroid surgery determined by a micro-costing approach. *Endocrine*. 2016 May 12.
 36. Conget I, Castaneda J, Petrovski G, Guerci B, Racault AS, Reznik Y, Cohen O, Runzis S, de Portu S, Aronson R; OpT2mise Study Group. The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study. *Diabetes Technol Ther*. 2016 Jan;18(1):22-8. doi: 10.1089/dia.2015.0159. Epub 2015 Aug 4.
 37. Rosato L, De Crea C, Bellantone R, Brandi ML, De Toma G, Filetti S, Miccoli P, Pacini F, Pelizzo MR, Pontecorvi A, Avenia N, De Pasquale L, Chiofalo MG, Gurrado A, Innaro N, La Valle G, Lombardi CP, Marini PL, Mondini G, Mullineris B, Pezzullo L, Raffaelli M, Testini M, De Palma M. Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB). *J Endocrinol Invest*. 2016 Apr 8. [Epub ahead of print]. PMID: 27059212.
 38. Mio C, Lavarone E, Conzatti K, Baldan F, Toffoletto B, Puppini C, Filetti S, Durante C, Russo D, Orlicchio A, Di Cristofano A, Di Loreto C, Damante G. MCM5 as a target of BET inhibitors in thyroid cancer cells. *Endocr Relat Cancer*. 2016 Feb 24. pii: ERC-15-0322.
 39. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine*. 2015 Dec 14. [Epub ahead of print] PMID:26668060.
 40. Sponziello M, Durante C, Filetti S. HAP2 Mutation and Nonmedullary Thyroid Cancer. *N Engl J Med*. 2015 Nov 19;373(21):2085-6. doi: 10.1056/NEJMc1511631#SA3. No abstract available. PMID: 26581004.
 41. Tallini G, de Biase D, Durante C, Acquaviva G, Bisceglia M, Bruno R, Bacchi Reggiani ML, Casadei GP, Costante G, Cremonini N, Lamartina L, Meringolo D, Nardi F, Pession A, Rhoden KJ, Ronga G, Torlontano M, Verrienti A, Visani M, Filetti S. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. *Mod Pathol*. 2015 Oct;28(10):1343-59. doi: 10.1038/modpathol.2015.92.
 42. Passon N, Bregant E, Sponziello M, Dima M, Rosignolo F, Durante C, Celano M, Russo D, Filetti S, Damante G. Somatic amplifications and deletions in genome of papillary thyroid carcinomas. *Endocrine*. 2015 Nov;50(2):453-64. doi: 10.1007/s12020-015-0592. PMID: 25863487.
 43. De Biase D, Gandolfi G, Ragazzi M, Eszlinger M, Sancisi V, Gugnoni M, Visani M, Pession A, Casadei GP, Durante C, Costante G, Bruno R, Torlontano M, Paschke R, Filetti S, Piana S, Frasoldati A, Tallini G, Ciarrocchi A. Tert promoter mutations in thyroid papillary microcarcinomas. *Thyroid*. 2015 Sep; 25(9): 1013-9. doi: 10.1089/thy.2015.0101. PMID: 26148423.
 44. Durante C, Costante G, Lucisano G, Bruno R, Meringolo D, Paciaroni A, Puxeddu E, Torlontano M, Tumino S, Attard M, Lamartina L, Nicolucci A, Filetti S. The natural history of benign thyroid nodules. *JAMA*. 2015 Mar 3;313(9):926-35. doi: 10.1001/jama.2015.0956.
 45. Baldan F, Mio C, Allegri L, Puppini C, Russo D, Filetti S, Damante G. Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line. *Int J Endocrinol*. 2015;2015:978371. doi: 10.1155/2015/978371.
 46. Lamartina L, Durante C, Filetti S, Cooper DS. Low-Risk Differentiated Thyroid Cancer and Radioiodine Remnant Ablation: A systematic review of the literature. *J Clin Endocrinol Metab*. 2015 May;100(5):1748-61. Doi: 10.1210/jc2014-3882. PMID: 25679996.
 47. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. *Expert Opin Drug Metab Toxicol*. 2015 Jan;11(1):125-37 doi: 10.1517/17425255.2015.986457. PMID: 25418019.
 48. Reznik Y, Huang S; OpT2mise Study Group. Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations. *Diabetes Technol Ther*. 2014 Nov;16(11):816-8, doi: 10.1089/dia.2014.0261. PMID: 25192407.

49. Reznik Y, Cohen O, Aronson R, Conget I, Runzis S, Castaneda J, Lee SW; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. *Lancet*. 2014 Oct 4;384(9950):1265-72. doi: 10.1016/S0140-6736(14)61037-0. PMID:24998009.
50. Micali S, Bulotta S, Puppini C, Territo A, Navarra M, Bianchi G, Damante G, Filetti S, Russo D. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. *BMC Cancer*. 2014 Apr 30;14:303. doi: 10.1186/1471-2407-14-303.
51. Baldan F, Lavarone E, Di Loreto C, Filetti S, Russo D, Damante G, Puppini C. Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene. *Mol Biol Rep*. 2014 Aug;41(8):5257-65. doi: 10.1007/s11033-014-3397-x.
52. Paolino D, Cosco D, Gaspari M, Celano M, Wolfram J, Voce P, Puxeddu E, Filetti S, Celia C, Ferrari M, Russo D, Fresta M. Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. *Biomaterials*. 2014 Aug;35(25):7101-9. doi: 10.1016/j.biomaterials.2014.04.088.
53. Sponziello M, Durante C, Boichard A, Dima M, Puppini C, Verrienti A, Tamburrano G, Di Rocco G, Redler A, Lacroix L, Bidart JM, Schlumberger M, Damante G, Russo D, Filetti S. Epigenetic-related gene expression profile in medullary thyroid cancer revealed the overexpression of the histone methyltransferases EZH2 and SMYD3 in aggressive tumours. *Mol Cell Endocrinol*. 2014 Jul 5;392(1-2):8-13. doi: 10.1016/j.mce.2014.04.016.
54. Aronson R, Cohen O, Conget I, Runzis S, Castaneda J, de Portu S, Lee S, Reznik Y; OpT2mise Study Group. OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes—research design and methods. *Diabetes Technol Ther*. 2014 Jul;16(7):414-20. doi: 10.1089/dia.2013.0363.
55. Durante C, Tognini S, Montesano T, Orlandi F, Torlontano M, Puxeddu E, Attard M, Costante G, Tumino S, Meringolo D, Bruno R, Trulli F, Totada M, Redler A, Ronga G, Filetti S, Monzani F. Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies. *Thyroid*. 2014 Jul;24(7):1139-45. doi: 10.1089/thy.2013.0698.
56. Puppini C, Durante C, Sponziello M, Verrienti A, Pecce V, Lavarone E, Baldan F, Campese AF, Boichard A, Lacroix L, Russo D, Filetti S, Damante G. Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation. *Endocrine*. 2014 Nov;47(2):528-36. doi: 10.1007/s12020-014-0204-3.
57. Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E. Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. *J Clin Endocrinol Metab*. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351.
58. Puxeddu E, Filetti S. BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? *Endocrine*. 2014 Apr;45(3):341-3. doi: 10.1007/s12020-013-0139-0.
59. D'Agostino M, Sponziello M, Puppini C, Celano M, Maggisano V, Baldan F, Biffoni M, Bulotta S, Durante C, Filetti S, Damante G, Russo D. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. *J Mol Endocrinol*. 2014 Jan 30;52(2):121-31. doi: 10.1530/JME-13-0160.
60. Maggisano V, Puppini C, Celano M, D'Agostino M, Sponziello M, Micali S, Navarra M, Damante G, Filetti S, & Russo D. Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells. *Endocrine*. 2014 Feb;45(1):148-52. doi: 10.1007/s12020-013-9972-4.
61. Grande E, Kreissl MC, Filetti S, Newbold K, Reinisch W, Robert C, Schlumberger M, Tolstrup LK, Zamorano JL, Capdevila J. Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies. *Adv Ther*. 2013 Nov;30(11):945-66. doi: 10.1007/s12325-013-0069-5.
62. Essig GF, Porter K, Schneider D, Debora A, Lindsey SC, Busonero G, Fineberg D, Fruci B, Boelaert K, Smit JW, Meijer JA, Duntas L, Sharma N, Costante G, Filetti S, Sippel RS, Biondi B, Topliss DJ, Pacini F, Maciel RM, Walz PC, Kloos RT. Fine Needle Aspiration and Medullary Thyroid Carcinoma: The Risk of Inadequate Preoperative Evaluation and Initial Surgery when Relying Upon FNAB Cytology Alone. *Endocr Pract*. 2013 Nov-Dec;19(6):920-7. doi: 10.4158/EP13143.OR.
63. Sponziello M, Lavarone E, Pegolo E, Di Loreto C, Puppini C, Russo MA, Bruno R, Filetti S, Durante C, Russo D, Di Cristofano A, Damante G. Molecular differences between human thyroid follicular adenoma and carcinoma revealed by analysis of a murine model of thyroid cancer. *Endocrinology*. 2013 Sep;154(9):3043-53. doi: 10.1210/en.2013-1028.
64. Bulotta S, Corradino R, Celano M, Maiuolo J, D'Agostino M, Oliverio M, Procopio A, Filetti S, Russo D. Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells. *J Mol Endocrinol*. 2013 Jun 29;51(1):181-9. doi: 10.1530/JME-12-0241.
65. Aghini-Lombardi F, Vitti P, Antonangeli L, Fiore E, Piaggi P, Pallara A, Consiglio E, Pinchera A; Southern Italy Study Group for Iodine Deficiency Disorders. The size of the community rather than its geographical location better defines the risk of iodine deficiency: results of an extensive survey in Southern Italy. *J Endocrinol Invest*. 2013 May;36(5):282-6.
66. Durante C, Paciaroni A, Plasmati K, Trulli F, Filetti S. Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. *Endocrine*. 2013 Oct;44(2):334-42. doi: 10.1007/s12020-013-9943-9.
67. Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for the post-operative management. *Endocr Relat Cancer*. 2013 Jun 24;20(4):R141-54. doi: 10.1530/ERC-13-0066.
68. Durante C, Montesano T, Torlontano M, Attard M, Monzani F, Tumino S, Costante G, Meringolo D, Bruno R, Trulli F, Massa M, Maniglia A, D'Apollo R, Giacomelli L, Ronga G, Filetti S; Papillary Thyroid Cancer: Time Course of Recurrences During Postsurgery Surveillance. *J Clin Endocrinol Metab*. 2013 Feb;98(2):636-42. doi: 10.1210/jc.2012-3401.
69. Russo D, Durante C, Bulotta S, Puppini C, Puxeddu E, Filetti S, Damante G. Targeting histone deacetylase in thyroid cancer. *Expert Opin Ther Targets*. 2013 Feb;17(2):179-93. doi: 10.1517/14728222.2013.740013.
70. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaidis M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med*. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799.
71. Micali S, Maggisano V, Cesinaro A, Celano M, Territo A, Reggiani Bonetti L, Sponziello M, Migaldi M, Navarra M, Bianchi G, Filetti S, Russo D. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. *J Endocrinol*. 2013 Jan 18;216(2):125-33. doi: 10.1530/JOE-12-0495.

72. Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocarelli P, Nicolucci A, Rivellesse AA, Squatrito S, Riccardi G; TOSCA.IT study group (Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Addition of either pioglitazone or a sulphonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. *Nutr Metab Cardiovasc Dis.* 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003.
73. D'Elia AV, Grimaldi F, Pizzolitto S, De Maglio G, Bregant E, Passon N, Franzoni A, Verrienti A, Tamburrano G, Durante C, Filetti S, Fogolari F, Russo D, Damante G. A new germline VHL gene mutation in three patients with apparently sporadic pheochromocytoma. *Clin Endocrinol (Oxf).* 2012 Sep 5. doi: 10.1111/cen.12032.
74. Lavarone E, Puppini C, Passon N, Filetti S, Russo D, Damante G. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. *Mol Cell Endocrinol.* 2012 Sep 5. pii: S0303-7207(12)00414-5. doi: 10.1016/j.mce.2012.08.019.
75. Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M; for the 1860-LIRA-DPP-4 Study Group. Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial. *Diabetes Care.* 2012 Oct;35(10):1986-93.]
76. Celano M, Sponziello M, Tallini G, Maggiano V, Bruno R, Dima M, Di Oto E, Redler A, Durante C, Sacco R, Filetti S, Russo D. Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations. *Endocrine.* 2013 Feb;43(1):147-53. doi: 10.1007/s12020-012-9747-3.
77. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giacomelli L, Ronga G, Filetti S. Long-Term Surveillance of Papillary Thyroid Cancer Patients Who Do Not Undergo Postoperative Radioiodine Remnant Ablation: Is There a Role for Serum Thyroglobulin Measurement? *J Clin Endocrinol Metab.* 2012 Aug;97(8):2748-2753.
78. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AM, Hollander P; NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet.* 2012 Apr 21;379(9825):1498-507. doi: 10.1016/S0140-6736(12)60205-0.
79. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, Durante C, Russo D, Filetti S, Damante G. Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells. *Thyroid.* 2012 May;22(5):487-93. doi: 10.1089/thy.2011.0360.
80. Maranghi M, Prudente S, D'Erasmo L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA, Morano S, Filetti S, Trischitta V. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals. *Nutr Metab Cardiovasc Dis.* 2013 Jun;23(6):505-10. doi: 10.1016/j.numecd.2011.11.003.]
81. Passon N, Puppini C, Lavarone E, Bregant E, Franzoni A, Hershman J, Fenton M, D'Agostino M, Durante C, Russo D, Filetti S, Damante G. CREM inhibits promoter activity of NIS gene in thyroid cancer cells. *Thyroid.* 2012 Feb 28.
82. D'Agostino M, Voce P, Celano M, Sponziello M, Moretti S, Maggiano V, Verrienti A, Durante C, Filetti S, Puxeddu E, Russo D. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. *Thyroid.* 2012 Feb;22(2):138-44. doi: 10.1089/thy.2011.0060.
83. Russo D, Costante G, Bruno R, Sponziello M, Tamburrano G, Dima M, Sacco R, Giacomelli L, Durante C, Filetti S. TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. *Endocrine.* 2011 Dec;40(3):492-4. doi: 10.1007/s12020-011-9525-7.
84. Voce P, D'Agostino M, Moretti S, Sponziello M, Rhoden K, Calcinaro F, Tamburrano G, Tallini G, Puxeddu E, Filetti S, Russo D, Durante C. Sunitinib inhibits tumor vascularity and growth but does not affect Akt and ERK phosphorylation in xenograft tumors. *Oncol Rep.* 2011 Nov;26(5):1075-80. doi: 10.3892/or.2011.1422.
85. Durante C, Filetti S. Management of Papillary Thyroid Cancer Patients in Absence of Postoperative Radioiodine Remnant Ablation: tailoring Follow-Up by Neck Sonography. *J Clin Endocrinol Metab.* 2011 Oct;96(10):3059-61. doi: 10.1210/jc.2011-1379.
86. Mastroianno S, Torlontano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, Durante C, Filetti S. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. *Endocrine.* 2011 Dec;40(3):481-5. doi: 10.1007/s12020-011-9501-2.
87. Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol.* 2011 Sep;165(3):455-63. doi: 10.1530/EJE-11-0283.
88. Russo D, Scipioni A, Durante C, Ferretti E, Gandini L, Maggiano V, Paoli D, Verrienti A, Costante G, Lenzi A, Filetti S. Expression and localization of the sodium/iodide symporter (NIS) in testicular cells. *Endocrine.* 2011 Aug;40(1):35-40. doi: 10.1007/s12020-011-9469-y.
89. Pianta A, Puppini C, Franzoni A, Fabbro D, Di Loreto C, Bulotta S, Deganuto M, Paron I, Tell G, Puxeddu E, Filetti S, Russo D, Damante G. Nucleophosmin is overexpressed in thyroid tumors. *Biochem Biophys Res Commun.* 2010 Jul 2;397(3):499-504. doi: 10.1016/j.bbrc.2010.05.142.
90. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M; for the 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. *Int J Clin Pract.* 2011 Mar 1. doi: 10.1111/j.1742-1241.2011.02656.x.
91. Russo D, Damante G, Puxeddu E, Durante C, Filetti S. Epigenetics of thyroid cancer and novel therapeutic targets. *J Mol Endocrinol.* 2011 Apr 28;46(3):R73-81. doi: 10.1530/JME-10-0150.
92. Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. *Expert Opin Investig Drugs.* 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163.
93. Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol.* 2012 Jun;49(3):193-7. doi: 10.1007/s00592-

- 011-0261-5.
94. Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? *Oncologist*. 2011;16(1):49-52. doi: 10.1634/theoncologist.2010-0344.
 95. Durante C, Attard M, Torlontano M, Ronga G, Monzani F, Costante G, Ferdeghini M, Tumino S, Meringolo D, Bruno R, De Toma G, Crocetti U, Montesano T, Dardano A, Lamartina L, Maniglia A, Giacomelli L, Filetti S. Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas. *J Clin Endocrinol Metab*. 2010 Nov;95(11):4882-8. doi: 10.1210/jc.2010-0762
 96. Zinnamosca L, Petramala L, Costeta D, Marinelli C, Sciomer S, Cavallaro G, Ciardi A, Massa R, De Toma G, Filetti S, Letizia C. Primary aldosteronism due to adrenocortical adenoma with concurrent ileum carcinoid tumor: case report. *Endocrine*. 2010 Dec;38(3):313-9. doi: 10.1007/s12020-010-9394-5.
 97. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res*. 2011 Jan;43(1):22-5. doi: 10.1055/s-0030-1265226.
 98. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8.
 99. Paolino D, Cosco D, Racanicchi L, Trapasso E, Celia C, Iannone M, Puxeddu E, Costante G, Filetti S, Russo D, Fresta M. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity. *J Control Release*. 2010 Jun 1;144(2):144-50. doi: 10.1016/j.jconrel.2010.02.021.
 100. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. *J Atheroscler Thromb*. 2010 Jun 30;17(6):539-45.
 101. Castellone MD, Verrienti A, Rao DM, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: Functional characterization. *Clin Endocrinol (Oxf)*. 2010 Oct;73(4):529-34. doi: 10.1111/j.1365-2265.2009.03757.
 102. Navarra M, Micali S, Lepore SM, Cesinaro AM, Celano M, Sighinolfi MC, De Gaetani C, Filetti S, Bianchi G, Russo D. Expression of the sodium/iodide symporter in human prostate adenocarcinoma. *Urology*. 2010 Apr;75(4):773-8. doi: 10.1016/j.urology.2009.10.011.
 103. Suh I, Filetti S, Vriens MR, Guerrero MA, Tumino S, Wong M, Shen WT, Kebebew E, Duh QY, Clark OH. Distinct loci on chromosome 1q21 and 6q22 predispose to familial nonmedullary thyroid cancer: a SNP array-based linkage analysis of 38 families. *Surgery*. 2009 Dec;146(6):1073-80. doi: 10.1016/j.surg.2009.09.012.
 104. Costeta D, Petramala L, Serra V, Pergolini M, Crescenzi E, Zinnamosca L, De Toma G, Ciardi A, Carbone I, Massa R, Filetti S, Letizia C. Clinical experience with pheochromocytoma in a single centre over 16 years. *High Blood Press Cardiovasc Prev*. 2009 Dec;16(4):183-93. doi: 10.2165/11530430.
 105. Puxeddu E, Filetti S. The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice. *Thyroid*. 2009;19(11):1145-7. doi: 10.1089/thy.2009.1601.
 106. Maranghi M, Pugliese F, Cianci R, Colotto M, Durante C, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, Filetti S. Atherosclerosis renal artery stenosis and in stent restenosis in diabetic patient: targeting on Diabetic Dyslipidemia is a key intervention. *J Endocrinol Invest*. 2009 Oct 15. doi: 10.3275/6567.
 107. Sponziello M, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D. Regulation of Sodium/Iodide Symporter and Lactoperoxidase Expression in four Human Breast Cancer Cell Lines. *J Endocrinol Invest*. 2009 Sep 30. doi: 10.3275/6522.
 108. Corleto VD, Costeta D, Petramala L, Panzuto F, Pagnini C, Masoni L, Verrienti A, Delle Fave G, Filetti S, Letizia C. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease. *JOP*. 2009;10(5):562-5.
 109. Marques LH, Ferraz-Filho JR, Lins-Filho ML, Maciel MG, Yoshitake R, Filetti S. Interictal SPECT in the presurgical evaluation in epileptic patients with normal MRI or bilateral mesial temporal sclerosis. *Arq Neuropsiquiatr*. 2009 Sep;67(3A):639-42.
 110. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V, Filetti S. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. *Diabetes Care*. 2009;32(8):1550-2. doi: 10.2337/dc09-0256.
 111. Costante G, Filetti S. Diagnosis: Thyroglobulin in fine-needle aspirates-a clue to metastasis? *Nat Rev Endocrinol*. 2009; 5(5):249-50. doi: 10.1038/nrendo.2009.55.
 112. Gatti A, Baroni MG, Romeo S, Mandosi E, Fallarino M, Bezzi M, Paciucci L, Filetti S, Morano S. A case of severe occult ectopic adrenocorticotropin syndrome treated with retrograde venous adrenal ablation using ethanol. *J Endocrinol Invest*. 2008 Dec;31(12):1135-6.
 113. Bruno R, Giannasio P, Chiarella R, Capula C, Russo D, Filetti S, Costante G. Identification of a neck lump as a lymph node metastasis from an occult contralateral papillary microcarcinoma of the thyroid: key role of thyroglobulin assay in the fine-needle aspirate. *Thyroid*. 2009;19(5):531-3. doi: 10.1089/thy.2009.0049.
 114. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L, Pignataro V, Bernini G, Giacchè V, Bacca A, Biondi B, Corona G, Di Trapani G, Grossrubatscher E, Reimondo G, Arnaldi G, Giacchetti G, Veglio F, Loli P, Colao A, Ambrosio MR, Terzolo M, Letizia C, Ercolino T, Opocher G; Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. *J Clin Endocrinol Metab*. 2009;94(5):1541-7. doi: 10.1210/jc.2008-2419.
 115. Franzoni A, Dima M, D'Agostino M, Puppini C, Fabbro D, Loreto CD, Pandolfi M, Puxeddu E, Moretti S, Celano M, Bruno R, Filetti S, Russo D, Damante G. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. *Thyroid*. 2009;19(3):247-55. doi: 10.1089/thy.2008.0235
 116. Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. *Ann Intern Med*. 2009 Jan 6;150(1):19-26.
 117. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. *Nat Clin Pract Endocrinol Metab*. 2009;5(1):35-44. doi: 10.1038/ncpendmet1023.

118. Petramala L, Cotesta D, Filetti S, Letizia C. Pigmented 'black' cardiac paraganglioma in a patient with a novel germ-line mutation. *Eur J Cardiothorac Surg.*; 35:189 doi: 10.1016/j.ejcts.2008.10.00.7.
119. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonfitto N, Dicembrino F, Varraso A, Meringolo D, Filetti S, Trischitta V, Torlontano M. Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. *Thyroid.* 2008;18(10):1049-53. doi: 10.1089/thy.2008.0160.
120. Capezzone M, Cantara S, Marchisotta S, Filetti S, De Santi MM, Rossi B, Ronga G, Durante C, Pacini F. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. *J Clin Endocrinol Metab.* 2008;93(10):3950-7. doi: 10.1210/jc.2008-0372.
121. Ferretti E, Tosi E, Po A, Scipioni A, Morisi R, Espinola MS, Russo D, Durante C, Schlumberger M, Screpanti I, Filetti S, Gulino A. Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. *J Clin Endocrinol Metab.* 2008;93(10):4080-7. doi: 10.1210/jc.2008-0528.
122. Durante C, Cava F, Paciaroni A, Filetti S. Benign thyroid nodules: diagnostic and therapeutic approach. *Recenti Prog Med.* 2008;99(5):263-70.
123. Celano M, Schenone S, Cosco D, Navarra M, Puxeddu E, Racanicchi L, Brullo C, Varano E, Alcaro S, Ferretti E, Botta G, Filetti S, Fresta M, Botta M, Russo D. Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo. *Endocr Relat Cancer.* 2008;15(2):499-510. doi: 10.1677/ERC-07-0243
124. Petramala L, Cavallaro G, Polistena A, Cotesta D, Verrienti A, Ciardi A, Lucia P, Filetti S, D'Erasmo E, De Toma G, Letizia C. Multiple catecholamine-secreting paragangliomas: diagnosis after hemorrhagic stroke in a young woman. *Endocr Pract.* 2008;14(3):340-6.
125. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. *Cardiology.* 2008;111(4):219-28. doi: 10.1159/000127442.
126. Puppini C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. *J Endocrinol.* 2008;197(2):401-8. doi: 10.1677/JOE-07-0618.
127. Xu J, Filetti S, Hershman JM. Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors. *Thyroid.* 2008;18(5):533-9. doi: 10.1089/thy.2007.0312
128. Puxeddu E, Durante C, Avenia N, Filetti S, Russo D. Clinical implications of BRAF mutation in thyroid carcinoma. *Trends Endocrinol Metab.* 2008;19(4):138-45. doi: 10.1016/j.tem.2007.12.003.
129. Vendrame F, Verrienti A, Parlapiano C, Filetti S, Dotta F, Morano S. Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. *Ann Clin Biochem.* 2008;45(Pt 2):218-20. doi: 10.1258/acb.2007.007117.
130. Morisi R, Celano M, Tosi E, Schenone S, Navarra M, Ferretti E, Costante G, Durante C, Botta G, D'Agostino M, Brullo C, Filetti S, Botta M, Russo D. Growth inhibition of medullary thyroid carcinoma cells by pyrazolopyrimidine derivatives. *J Endocrinol Invest.* 2007;30(10):RC31-4.
131. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. *J Clin Endocrinol Metab.* 2008;93(3):910-3.
132. Scipioni A, Ferretti E, Soda G, Tosi E, Bruno R, Costante G, Meringolo D, Arturi F, Durante C, Amorosi A, Foschini MP, Nardi F, Russo D, Filetti S. hNIS protein in thyroid: the iodine supply influences its expression and localization. *Thyroid.* 2007;17(7):613-8.
133. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. *J Clin Endocrinol Metab.* 2007 ;92(7):2840-3.
134. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, Durante C, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. *Thyroid.* 2007;17(4):363-6.
135. Faggiano A, Caillou B, Lacroix L, Talbot M, Filetti S, Bidart JM, Schlumberger M. Functional characterization of human thyroid tissue with immunohistochemistry. *Thyroid.* 2007;17(3):203-11.
136. Schlumberger M, Lacroix L, Russo D, Filetti S, Bidart JM. Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients. *Nat Clin Pract Endocrinol Metab.* 2007;3(3):260-9.
137. Maranghi M, Coletta P, Durante C, Pergolini D, Filetti S. Cardiovascular disease and metabolic syndrome. *Recenti Prog Med.* 2006;97(12):719-26.
138. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab.* 2007 ;92(2):450-5.
139. Filetti S, Durante C, Torlontano M. Nonsurgical approaches to the management of thyroid nodules. *Nat Clin Pract Endocrinol Metab.* 2006;2(7):384-94.
140. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab.* 2005;1(1):32-40.
141. Pines A, Bivi N, Vascotto C, Romanello M, D'Ambrosio C, Scaloni A, Damante G, Morisi R, Filetti S, Ferretti E, Quadrifoglio F, Tell G. Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. *J Cell Physiol.* 2006;209(1):44-55.
142. Caliumi C, Cotesta D, Petramala L, Lorio M, Salvati M, Filetti S, De Toma G, D'Erasmo E, Letizia C. An unusual association of cerebral meningioma, parathyroid adenoma and thyroid papillary carcinoma. *Tumori.* 2006;92(2):178-80.
143. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, Filetti S, Schlumberger M, Bidart JM. HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. *Clin Endocrinol (Oxf).* 2006;64(4):398-404.
144. D'Aloiso L, Carlomagno F, Bisceglia M, Anaganti S, Ferretti E, Verrienti A, Arturi F, Scarpelli D, Russo D, Santoro M, Filetti S. Clinical case seminar: in vivo and in vitro characterization of a novel germline RET mutation associated with low-penetrant nonaggressive familial medullary thyroid carcinoma. *J Clin Endocrinol Metab.* 2006;91(3):754-9

145. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, Filetti S, Trischitta V. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab.* 2006;91(1):60-3.
146. Bruno R, Ferretti E, Tosi E, Arturi F, Giannasio P, Mattei T, Scipioni A, Presta I, Morisi R, Gulino A, Filetti S, Russo D. Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. *J Clin Endocrinol Metab.* 2005;90(10):5692-7.
147. Presta I, Arturi F, Ferretti E, Mattei T, Scarpelli D, Tosi E, Scipioni A, Celano M, Gulino A, Filetti S, Russo D. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. *BMC Cancer.* 2005 19;5:80.
148. Ferretti E, Arturi F, Mattei T, Scipioni A, Tell G, Tosi E, Presta I, Morisi R, Lacroix L, Gulino A, Russo D, Damante G, Filetti S. Expression, regulation, and function of paired-box gene 8 in the human placenta and placental cancer cell lines. *Endocrinology.* 2005;146(9):4009-15.
149. Puppini C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. *Endocrinology.* 2005 ;146(9):3967-74.
150. Russo D, Bisca A, Celano M, Talamo F, Arturi F, Scipioni A, Presta I, Bulotta S, Ferretti E, Filetti S, Scaloni A, Damante G, Tell G. Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells. *J Endocrinol Invest.* 2005;28(2):137-44.
151. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. *Eur J Endocrinol.* 2005 ;152(1):1-9.
152. Scarpelli D, D'Aloiso L, Arturi F, Scillitani A, Presta I, Bisceglia M, Cristofaro C, Russo D, Filetti S. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. *J Endocrinol Invest.* 2004;27(11):1015-21.
153. Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, Filetti S, Schlumberger M. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. *J Endocrinol Invest.* 2004;27(11):1010-4.
154. Arturi F, Ferretti E, Presta I, Mattei T, Scipioni A, Scarpelli D, Bruno R, Lacroix L, Tosi E, Gulino A, Russo D, Filetti S. Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line. *J Clin Endocrinol Metab.* 2005;90(4):2321-6.
155. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroli D, Filetti S, Fresta M, Russo D. Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. *BMC Cancer.* 2004;4:63.
156. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. *J Clin Endocrinol Metab.* 2004;89(7):3402-7.
157. Tell G, Pines A, Arturi F, Cesaratto L, Adamson E, Puppini C, Presta I, Russo D, Filetti S, Damante G. Control of phosphatase and tensin homolog (PTEN) gene expression in normal and neoplastic thyroid cells. *Endocrinology.* 2004;145(10):4660-6.
158. Romeo S, Menzaghi C, Bruno R, Sentinelli F, Fallarino M, Fioretti F, Filetti S, Balsamo A, Di Mario U, Baroni MG. Search for genetic variants in the retinoid X receptor-gamma-gene by polymerase chain reaction-single-strand conformation polymorphism in patients with resistance to thyroid hormone without mutations in thyroid hormone receptor beta gene. *Thyroid.* 2004;14(5):355-8.
159. Torrente I, Arturi F, D'Aloiso L, Colosimo A, De Luca A, Ferretti E, Russo D, Chiefari E, Scarpelli D, Bisceglia M, Dallapiccola B, Filetti S. Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma. *J Endocrinol Invest.* 2004;27(2):111-6.
160. Corsetti F, Chianelli M, Cornelissen B, Van de Wiele C, D'Alessandria C, Slegers G, Mather SJ, Di Mario U, Filetti S, Scopinaro F, Signore A. Radioiodinated recombinant human TSH: a novel radiopharmaceutical for thyroid cancer metastases detection. *Cancer Biother Radiopharm.* 2004;19(1):57-63.
161. Puppini C, Presta I, D'Elia AV, Tell G, Arturi F, Russo D, Filetti S, Damante G. Functional interaction among thyroid-specific transcription factors: Pax8 regulates the activity of Hex promoter. *Mol Cell Endocrinol.* 2004;214(1-2):117-25.
162. Costante G, Crocetti U, Schifino E, Ludovico O, Capula C, Nicotera M, Arturi F, Filetti S. Slow growth of benign thyroid nodules after menopause: no need for long-term thyroxine suppressive therapy in post-menopausal women. *J Endocrinol Invest.* 2004;27(1):31-6.
163. Puppini C, Arturi F, Ferretti E, Russo D, Sacco R, Tell G, Damante G, Filetti S. Transcriptional regulation of human sodium/iodide symporter gene: a role for redox factor-1. *Endocrinology.* 2004;145(3):1290-3.
164. Arturi F, Scarpelli D, Coco A, Sacco R, Bruno R, Filetti S, Russo D. Thyrotropin receptor mutations and thyroid hyperfunctioning adenomas ten years after their first discovery: unresolved questions. *Thyroid.* 2003;13(4):341-3.
165. Celano M, Arturi F, Presta I, Bruno R, Scarpelli D, Calvagno MG, Cristofaro C, Bulotta S, Giannasio P, Sacco R, Filetti S, Russo D. Expression of adenyl cyclase types III and VI in human hyperfunctioning thyroid nodules. *Mol Cell Endocrinol.* 2003;203(1-2):129-35
166. Puppini C, D'Elia AV, Pellizzari L, Russo D, Arturi F, Presta I, Filetti S, Bogue CW, Denson LA, Damante G. Thyroid-specific transcription factors control Hex promoter activity. *Nucleic Acids Res.* 2003;31(7):1845-52.
167. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. *Eur J Endocrinol.* 2003;148(1):19-24.
168. Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M, Filetti S. Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation? *BMC Cancer.* 2002 Dec 10;2:35.
169. Arturi F, Presta I, Scarpelli D, Bidart JM, Schlumberger M, Filetti S, Russo D. Stimulation of iodide uptake by human chorionic gonadotropin in FRTL-5 cells: effects on sodium/iodide symporter gene and protein expression. *Eur J Endocrinol.* 2002 Nov;147(5):655-61.
170. Russo D, Celano M, Bulotta S, Bruno R, Arturi F, Giannasio P, Filetti S, Damante G, Tell G. APE/Ref-1 is increased in nuclear fractions of human thyroid hyperfunctioning nodules. *Mol Cell Endocrinol.* 2002 Aug 30;194(1-2):71-6.
171. Arturi F, Chiefari E, Tumino S, Russo D, Squatrito S, Chazenbalk G, Persani L, Rapoport B, Filetti S.

- Similarities and differences in the phenotype of members of an Italian family with hereditary non-autoimmune hyperthyroidism associated with an activating TSH receptor germline mutation. *J Endocrinol Invest.* 2002 Sep;25(8):696-701.
172. Giardina E, Capon F, D'Apice MR, Amati F, Arturi F, Filetti S, Bonifazi E, Pucci S, Conte C, Novelli G. Mutational analysis of Peroxiredoxin IV: exclusion of a positional candidate for multinodular goitre. *BMC Med Genet.* 2002 Jul 23;3:5.
 173. Arturi F, Lacroix L, Presta I, Scarpelli D, Caillou B, Schlumberger M, Russo D, Bidart JM, Filetti S. Regulation by human chorionic gonadotropin of sodium/iodide symporter gene expression in the JAr human choriocarcinoma cell line. *Endocrinology.* 2002 Jun;143(6):2216-20.
 174. Costante G, Grasso L, Schifino E, Marasco MF, Crocetti U, Capula C, Chiarella R, Ludovico O, Nocera M, Parlato G, Filetti S. Iodine deficiency in Calabria: characterization of endemic goiter and analysis of different indicators of iodine status region-wide. *J Endocrinol Invest.* 2002 Mar;25(3):201-7.
 175. Lombardo F, Baudin E, Chiefari E, Arturi F, Bardet S, Caillou B, Conte C, Dallapiccola B, Giuffrida D, Bidart JM, Schlumberger M, Filetti S. Familial medullary thyroid carcinoma: clinical variability and low aggressiveness associated with RET mutation at codon 804. *J Clin Endocrinol Metab.* 2002 Apr;87(4):1674-80.
 176. Belfiore A, Russo D, Vigneri R, Filetti S. Graves' disease, thyroid nodules and thyroid cancer. *Clin Endocrinol (Oxf).* 2001 Dec;55(6):711-8.
 177. D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manfioletti G, Gattei V, Mack DL, Cataldi P, Filetti S, Di Loreto C, Damante G. Expression and localization of the homeodomain-containing protein HEX in human thyroid tumors. *J Clin Endocrinol Metab.* 2002 Mar;87(3):1376-83.
 178. Biondi B, Palmieri EA, Filetti S, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. *Lancet.* 2002 Mar 2;359(9308):799-800.
 179. Boland A, Magnon C, Filetti S, Bidart JM, Schlumberger M, Yeh P, Perricaudet M. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. *Thyroid.* 2002 Jan;12(1):19-26.
 180. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C, Filetti S, Bidart JM, Schlumberger M. Expression of nicotinamide adenine dinucleotide phosphate oxidase flavoprotein DUOX genes and proteins in human papillary and follicular thyroid carcinomas. *Thyroid.* 2001 Nov;11(11):1017-23.
 181. Russo D, Bulotta S, Bruno R, Arturi F, Giannasio P, Derwahl M, Bidart JM, Schlumberger M, Filetti S. Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. *Eur J Endocrinol.* 2001 Nov;145(5):591-7.
 182. Mian C, Lacroix L, Bidart JM, Caillou B, Filetti S, Schlumberger M. Sodium/iodide symporter in thyroid cancer. *Exp Clin Endocrinol Diabetes.* 2001;109(1):47-51.
 183. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. *Eur J Endocrinol.* 2001;145(2):129-35.
 184. Russo D, Arturi F, Bulotta S, Pellizzari L, Filetti S, Manzini G, Damante G, Tell G. *Apel/Ref-1* expression and cellular localization in human thyroid carcinoma cell lines. *J Endocrinol Invest.* 2001;24(3):RC10-2.
 185. Chiefari E, Chiarella R, Crocetti U, Tardio B, Arturi F, Russo D, Trischitta V, Filetti S, Zingrillo M. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC. *Horm Metab Res.* 2001; 33(1):52-6.
 186. Lombardo F, Filetti S, Crocetti U, Schlumberger M. Medullary thyroid carcinoma and lack of renal agenesis. *Thyroid* 2001;11(1):93.
 187. Russo D, Manole D, Arturi F, Suarez HG, Schlumberger M, Filetti S, Derwahl M. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas. *Thyroid.* 2001;11(1):37-9.
 188. Lacroix L, Mian C, Caillou B, Talbot M, Filetti S, Schlumberger M, Bidart JM. *Na⁺/I⁻* symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. *Eur J Endocrinol.* 2001;144(3):297-302.
 189. Orlandi F, Chiefari E, Caraci P, Mussa A, Gonzatto I, De Giuli P, Giuffrida D, Angeli A, Filetti S. RET proto-oncogene mutation in a mixed medullary-follicular thyroid carcinoma. *J Endocrinol Invest.* 2001;24(1):51-5.
 190. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Saccà L, Filetti S, Lombardi G, Perticone F. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab.* 2000;85(12):4701-5.
 191. Camacho P, Gordon D, Chiefari E, Yong S, DeJong S, Pitale S, Russo D, Filetti S. A Phe 486 thyrotropin receptor mutation in an autonomously functioning follicular carcinoma that was causing hyperthyroidism. *Thyroid.* 2000;10(11):1009-12.
 192. Bidart JM, Lacroix L, Evain-Brion D, Caillou B, Lazar V, Frydman R, Bellet D, Filetti S, Schlumberger M. Expression of *Na⁺/I⁻* symporter and Pendred syndrome genes in trophoblast cells. *J Clin Endocrinol Metab.* 2000;85(11):4367-72.
 193. Russo D, Betterle C, Arturi F, Chiefari E, Girelli ME, Filetti S. A novel mutation in the thyrotropin (TSH) receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. *J Clin Endocrinol Metab.* 2000;85(11):4238-42.
 194. Arturi F, Russo D, Giuffrida D, Schlumberger M, Filetti S. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. *Eur J Endocrinol.* 2000;143(5):623-7.
 195. Du Villard JA, Wicker R, Crespo P, Russo D, Filetti S, Gutkind JS, Sarasin A, Suárez HG. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation. *Oncogene.* 2000;19(42):4896-905.
 196. Capon F, Tacconelli A, Giardina E, Sciacchitano S, Bruno R, Tassi V, Trischitta V, Filetti S, Dallapiccola B, Novelli G. Mapping a dominant form of multinodular goiter to chromosome Xp22. *Am J Hum Genet.* 2000;67(4):1004-7.
 197. Persani L, Lania A, Alberti L, Romoli R, Mantovani G, Filetti S, Spada A, Conti M. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. *J Clin Endocrinol Metab.* 2000;85(8):2872-8.
 198. Boland A, Ricard M, Opolon P, Bidart JM, Yeh P, Filetti S, Schlumberger M, Perricaudet M. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. *Cancer Res.* 2000;60(13):3484-92.
 199. Bidart JM, Mian C, Lazar V, Russo D, Filetti S, Caillou B, Schlumberger M. Expression of pendrin and the Pendred syndrome (PDS) gene in human thyroid tissues. *J Clin Endocrinol Metab.* 2000;85(5):2028-33.
 200. Brunetti A, Chiefari E, Filetti S, Russo D. The 3',5'-cyclic adenosine monophosphate response element

- binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. *Endocrinology*. 2000;141(2):722-30.
201. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. *Eur J Endocrinol*. 1999;141(5):443-57.
 202. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, Schlumberger M. Expression of the Na⁺/I⁻ symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. *J Clin Endocrinol Metab*. 1999;84(9):3228-34.
 203. Russo D, Arturi F, Pontecorvi A, Filetti S. Genetic Analysis in Fine-needle Aspiration of the Thyroid: A New Tool for the Clinic. *Trends Endocrinol Metab*. 1999;10(7):280-285.
 204. Russo D, Arturi F, Chiefari E, Filetti S. Thyrotropin receptor: a role for thyroid tumorigenesis? *Forum (Genova)*. 1999;9(2):166-75.
 205. Trapasso F, Iuliano R, Chiefari E, Arturi F, Stella A, Filetti S, Fusco A, Russo D. Iodide symporter gene expression in normal and transformed rat thyroid cells. *Eur J Endocrinol*. 1999;140(5):447-51.
 206. Russo D, Wong MG, Costante G, Chiefari E, Treseler PA, Arturi F, Filetti S, Clark OH. A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. *Thyroid*. 1999; 9(1):13-7.
 207. Frittitta L, Sciacca L, Catalfamo R, Ippolito A, Gangemi P, Pezzino V, Filetti S, Vigneri R. Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis? *Cancer*. 1999;85(2):492-8.
 208. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM. Na⁺/I⁻ symporter distribution in human thyroid tissues: an immunohistochemical study. *J Clin Endocrinol Metab*. 1998;83(11):4102-6.
 209. Arturi F, Capula C, Chiefari E, Filetti S, Russo D. Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. *Exp Clin Endocrinol Diabetes*. 1998;106(3):234-6.
 210. Chiefari E, Russo D, Giuffrida D, Zampa GA, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. *J Endocrinol Invest*. 1998;21(6):358-64.
 211. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S. Iodide symporter gene expression in human thyroid tumors. *J Clin Endocrinol Metab*. 1998;83(7):2493-6.
 212. Russo D, Arturi F, Chiefari E, Meringolo D, Bianchi D, Bellanova B, Filetti S. A case of metastatic medullary thyroid carcinoma: early identification before surgery of an RET proto-oncogene somatic mutation in fine-needle aspirate specimens. *J Clin Endocrinol Metab*. 1997;82(10):3378-82.
 213. Costante G, Grasso L, Ludovico O, Marasco MF, Nocera M, Schifino E, Rivalta L, Capula C, Chiarella R, Filetti S, Parlato G. The statistical analysis of neonatal TSH results from congenital hypothyroidism screening programs provides a useful tool for the characterization of moderate iodine deficiency regions. *J Endocrinol Invest*. 1997;20(5):251-6.
 214. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R, Filetti S. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. *J Clin Endocrinol Metab*. 1997;82(5):1638-41.
 215. Russo D, Tumino S, Arturi F, Vigneri P, Grasso G, Pontecorvi A, Filetti S, Belfiore A. Detection of an activating mutation of the thyrotropin receptor in a case of an autonomously hyperfunctioning thyroid insular carcinoma. *J Clin Endocrinol Metab*. 1997;82(3):735-8.
 216. Moretti F, Farsetti A, Soddu S, Misiti S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. *Oncogene*. 1997;14(6):729-40.
 217. Russo D, Arturi F, Chiefari E, Filetti S. Molecular insights into TSH receptor abnormality and thyroid disease. *J Endocrinol Invest*. 1997;20(1):36-47.
 218. Kakinuma A, Chazenbalk G, Filetti S, McLachlan SM, Rapoport B. Both the 5' and 3' noncoding regions of the thyrotropin receptor messenger ribonucleic acid influence the level of receptor protein expression in transfected mammalian cells. *Endocrinology*. 1996;137(7):2664-9.
 219. Derwahl M, Hamacher C, Russo D, Broecker M, Manole D, Schatz H, Kopp P, Filetti S. Constitutive activation of the Gs alpha protein-adenylate cyclase pathway may not be sufficient to generate toxic thyroid adenomas. *J Clin Endocrinol Metab*. 1996;81(5):1898-904.
 220. Russo D, Arturi F, Suarez HG, Schlumberger M, Du Villard JA, Crocetti U, Filetti S. Thyrotropin receptor gene alterations in thyroid hyperfunctioning adenomas. *J Clin Endocrinol Metab*. 1996;81(4):1548-51.
 221. Bourdoux PP, Ermans AM, Mukalay wa Mukalay A, Filetti S, Vigneri R. Iodine-induced thyrotoxicosis in Kivu, Zaire. *Lancet*. 1996 ; 347(9000):552-3.
 222. Russo D, Arturi F, Schlumberger M, Caillou B, Monier R, Filetti S, Suárez HG. Activating mutations of the TSH receptor in differentiated thyroid carcinomas. *Oncogene*. 1995;11(9):1907-11.
 223. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard JA, Caillou B, Monier R, Rapoport B, Filetti S. Genetic alterations in thyroid hyperfunctioning adenomas. *J Clin Endocrinol Metab*. 1995;80(4):1347-51.
 224. Bartolone L, Regalbuto C, Benvenega S, Filetti S, Trimarchi F, Pontecorvi A. Three new mutations of thyroid hormone receptor-beta associated with resistance to thyroid hormone. *J Clin Endocrinol Metab*. 1994;79(1):323-6.
 225. Russo D, Damante G, Foti D, Costante G, Filetti S. Different molecular mechanisms are involved in the multihormonal control of glucose transport in FRTL5 rat thyroid cells. *J Endocrinol Invest*. 1994;17(5):323-7.
 226. Foti D, Damante G, Russo D, Distefano M, Grasso G, Fusco A, Filetti S. Molecular mechanisms of the increased glucose transport in transformed FRTL-5 rat thyroid cells. *Biochem Biophys Res Commun*. 1993; 191(1):289-94.
 227. Foti D, Russo D, Costante G, Filetti S. The biological activity of bovine and human thyrotropin is differently affected by trypsin treatment of human thyroid cells: thyroid-stimulating antibody is related to human thyrotropin. *J Clin Endocrinol Metab*. 1991;73(4):710-6.
 228. Filetti S, Foti D, Costante G, Rapoport B. Recombinant human thyrotropin (TSH) receptor in a radioreceptor assay for the measurement of TSH receptor autoantibodies. *J Clin Endocrinol Metab*. 1991;72(5):1096-101.
 229. Foti D, Catalfamo R, Russo D, Costante G, Filetti S. Lack of relationship between 3',5'cyclic adenosine monophosphate desensitization and thyrotropin receptor down regulation in the rat thyroid cell line FRTL5. *J Endocrinol Invest*. 1991;14(3):213-8.
 230. Damante G, Russo D, Foti D, Grasso G, Filetti S. Effect of thyrotropin and cAMP on FRTL5 cell growth in a serum free medium. *J Endocrinol Invest*. 1990;13(5):397-402.

231. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R. Increased aggressiveness of thyroid cancer in patients with Graves' disease. *J Clin Endocrinol Metab.* 1990;70(4):830-5.
232. Kaufman KD, Filetti S, Seto P, Rapoport B. Recombinant human thyroid peroxidase generated in eukaryotic cells: a source of specific antigen for the immunological assay of antimicrosomal antibodies in the sera of patients with autoimmune thyroid disease. *J Clin Endocrinol Metab.* 1990; 70(3):724-8.
233. Belfiore A, Giuffrida D, La Rosa GL, Ippolito O, Russo G, Fiumara A, Vigneri R, Filetti S. High frequency of cancer in cold thyroid nodules occurring at young age. *Acta Endocrinol (Copenh).* 1989; 121(2):197-202.
234. Damante G, Chazenbalk G, Russo D, Rapoport B, Foti D, Filetti S. Thyrotropin regulation of thyroid peroxidase messenger ribonucleic acid levels in cultured rat thyroid cells: evidence for the involvement of a nontranscriptional mechanism. *Endocrinology.* 1989;124(6):2889-94.
235. Filetti S, Belfiore A, Amir SM, Daniels GH, Ippolito O, Vigneri R, Ingbar SH. The role of thyroid-stimulating antibodies of Graves' disease in differentiated thyroid cancer. *N Engl J Med.* 1988;318(12):753-9.
236. Damante G, Filetti S, Rapoport B. The functional activity of the rat c-Ha-ras promoter requires the coordinate involvement of multiple elements. *FEBS Lett.* 1987;225(1-2):264-8.
237. Magnusson RP, Chazenbalk GD, Gestautas J, Seto P, Filetti S, DeGroot LJ, Rapoport B. Molecular cloning of the complementary deoxyribonucleic acid for human thyroid peroxidase. *Mol Endocrinol.* 1987; 1(11):856-61.
238. Damante G, Filetti S, Rapoport B. Studies on the promoter region of the c-Ha-ras gene in FRTL5 rat thyroid cells. *Mol Endocrinol.* 1987;1(10):729-34.
239. Damante G, Foti D, Catalfamo R, Filetti S. Desensitization of the thyroid cyclic AMP response to thyroid stimulating immunoglobulin: comparison with TSH. *Metabolism.* 1987;36(8):768-73.
240. Filetti S, Damante G, Foti D. Thyrotropin stimulates glucose transport in cultured rat thyroid cells. *Endocrinology.* 1987;120(6):2576-81.
241. Trischitta V, Damante G, Foti D, Filetti S. Insulin binding and biological activities in the FRTL-5 rat thyroid cell line. *Metabolism.* 1987;36(4):379-83.
242. Hirayu H, Seto P, Magnusson RP, Filetti S, Rapoport B. Molecular cloning and partial characterization of a new autoimmune thyroid disease-related antigen. *J Clin Endocrinol Metab.* 1987;64(3):578-84.
243. Damante G, Filetti S, Rapoport B. Nucleotide sequence and characterization of the 5' flanking region of the rat Ha-ras protooncogene. *Proc Natl Acad Sci U S A.* 1987;84(3):774-8.
244. Karpman BA, Rapoport B, Filetti S, Fisher DA. Treatment of neonatal hyperthyroidism due to Graves' disease with sodium ipodate. *J Clin Endocrinol Metab.* 1987;64(1):119-23.
245. Rapoport B, Damante G, Dere W, Filetti S. Studies on the promoter region of the c-Ha-ras oncogene. *Horm Metab Res Suppl.* 1987;17:57-62. No abstract available.
246. Filetti S, Vetri M, Damante G, Belfiore A. Thyroid autoregulation: effect of iodine on glucose transport in cultured thyroid cells. *Endocrinology.* 1986;118(4):1395-400.
247. Rapoport B, Filetti S, Seto P. On the mechanism of 'escape' from desensitization of the cyclic AMP response to TSH in cultured human thyroid cells. *Mol Cell Endocrinol.* 1984 Jul;36(3):181-6.
248. Filetti S, Rapoport B. Autoregulation by iodine of thyroid protein synthesis: influence of iodine on amino acid transport in cultured thyroid cells. *Endocrinology.* 1984;114(4):1379-85.
249. Rapoport B, Greenspan FS, Filetti S, Pepitone M. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin. *J Clin Endocrinol Metab.* 1984;58(2):332-8.
250. Filetti S, Rapoport B. Evidence that organic iodine attenuates the adenosine 3',5'-monophosphate response to thyrotropin stimulation in thyroid tissue by an action at or near the adenylate cyclase catalytic unit. *Endocrinology.* 1983 Nov;113(5):1608-15.
251. Rapoport B, Filetti S, Takai NA. Differential effect of protein synthesis inhibition on TSH desensitization at different stages of primary thyroid cell culture. *Endocrinology.* 1983;112(5):1874-6.
252. Pezzino V, Distefano G, Belfiore A, Filetti S, Mazzone D, Grasso S. Role of thyrotrophin-releasing hormone in the development of pituitary-thyroid axis in four anencephalic infants. *Acta Endocrinol (Copenh).* 1982 Dec;101(4):538-41.
253. Rapoport B, Filetti S, Takai N, Seto P, Halverson G. Studies on the cyclic AMP response to thyroid stimulating immunoglobulin (TSI) and thyrotropin (TSH) in human thyroid cell monolayers. *Metabolism.* 1982 Nov;31(11):1159-67.
254. Rapoport B, Filetti S, Takai N, Seto P. Studies on the desensitization of the cyclic AMP response to thyrotropin in thyroid tissue. *FEBS Lett.* 1982;146(1):23-7.
255. Takai NA, Rapoport B, Filetti S. High performance gel permeation chromatography of bovine thyrotropin (TSH): effect of column stability and mobile phase variation. *Horm Metab Res.* 1982; 14(8):429-32.
256. Rapoport B, Takai NA, Filetti S. Evidence for species specificity in the interaction between thyrotropin and thyroid-stimulating immunoglobulin and their receptor in thyroid tissue. *J Clin Endocrinol Metab.* 1982;54(5):1059-62.
257. Filetti S, Rapoport B. Inhibitors of specific aminoacyl-tRNA synthetases prevent thyrotropin-induced desensitization in cultured human thyroid cells. *J Biol Chem.* 1982 Feb 10;257(3):1342-6.
258. Filetti S, Rapoport B, Aron DC, Greenspan FC, Wilson CB, Fraser W. TSH and TSH-subunit production by human thyrotrophic tumour cells in monolayer culture. *Acta Endocrinol (Copenh).* 1982;99(2):224-31.
259. Filetti S, Takai N, Rapoport B. Influence of cell density on desensitization of the thyroid cell cyclic adenosine 3',5'-monophosphate response to thyrotropin stimulation. *Endocrinology.* 1981;109(4):1156-63.
260. Takai NA, Filetti S, Rapoport B. Studies on the bioactivity of radioiodinated highly purified bovine thyrotropin: analytical polyacrylamide gel electrophoresis. *Endocrinology.* 1981;109(4):1144-9.
261. Filetti S, Rapoport B. Hormonal stimulation of eucaryotic cell ADP-ribosylation. *J Clin Invest.* 1981;68(2):461-7.
262. Filetti S, Takai NA, Rapoport B. Insulin receptor down-regulation, prevention at a post-receptor site. *Endocrinology.* 1981;108(6):2409-11.
263. Hinds WE, Takai N, Rapoport B, Filetti S, Clark OH. Thyroid-stimulating immunoglobulin bioassay using cultured human thyroid cells. *J Clin Endocrinol Metab.* 1981;52(6):1204-10.
264. Filetti S, Takai NA, Rapoport B. Prevention by nicotinamide of desensitization to thyrotropin stimulation in cultured human thyroid cells. *J Biol Chem.* 1981;256(3):1072-5.
265. Pezzino V, Filetti S, Belfiore A, Proto S, Donzelli G, Vigneri R. Serum thyroglobulin levels in the newborn. *J Clin Endocrinol Metab.* 1981;52(2):364-6.
266. Takai NA, Filetti S, Rapoport B. Studies on the bioactivity of radiolabeled, highly-purified bovine thyrotropin. *Biochem Biophys Res Commun.* 1980;97(2):566-73.
267. Grasso S, Filetti S, Mazzone D, Pezzino V, Vigo R, Vigneri R. Thyroid-pituitary function in eight anencephalic infants. *Acta Endocrinol (Copenh).* 1980;93(4):396-401.

268. Filetti S, Catanuso A, Lisi E, Pezzino V, Sangiorgio L, Squatrito S, Vigneri R. Measurement of reverse triiodothyronine in dried blood spot: methodology and clinical application as a screening procedure for detection of congenital hypothyroidism. *Metabolism*. 1980;29(2):141-5.
269. Vigneri R, Filetti S, Lisi E, Squatrito S, Polosa P. Reverse T3 and screening for congenital hypothyroidism. *J Endocrinol Invest*. 1978 ;1(4):385-7. No abstract available.
270. Delange F, Vigneri R, Trimarchi F, Filetti S, Pezzino V, Squatrito S, Bourdoux P, Ermans AM. Etiological factors of endemic goiter in north-eastern Sicily. *J Endocrinol Invest*. 1978;1(2):137-42
271. Pezzino V, Vigneri R, Squatrito S, Filetti S, Camus M, Polosa P. Increased serum thyroglobulin levels in patients with nontoxic goiter. *J Clin Endocrinol Metab*. 1978;46(4):653-7.
272. Pezzino V, Cozzani P, Filetti S, Galbiati A, Lisi E, Squatrito S, Vigneri R. A radioimmunoassay for human thyroglobulin: methodology and clinical applications. *Eur J Clin Invest*. 1977;7(6):503-8.
273. Filetti S, Camus M, Rodesch F, Delange F, Vigneri R, Ermans AM. Decreased reverse triiodothyronine (RT3) concentration in amniotic fluid in fetal hypothyroidism. *Arch Dis Child*. 1977;52(5):430-1. No abstract available.
274. Vigneri R, Pezzino V, Filetti S, Squatrito S, Corso A, Maricchiolo M, Polosa P, Scapagnini U. Thyrotropin and prolactin response to intraspinal TRH administration in man. *Neuroendocrinology*. 1977;23(3):171-80.
275. Vigneri R, Squatrito S, Pezzino V, Filetti S, Branca S, Polosa P. Growth hormone levels in diabetes. Correlation with the clinical control of the disease. *Diabetes*. 1976;25(3):167-72.
276. Vigneri R, Pezzino V, Filetti S, Squatrito S, Galbiati A, Polosa P. Effect of dexamethasone on thyroid hormone response to TSH. *Metabolism*. 1975;24(11):1209-13.
277. Vigneri R, Squatrito S, Pezzino V, Filetti S, Polosa P. The effect of short-term triiodothyronine administration on thyroxine response to exogenous TSH in man. *J Clin Endocrinol Metab*. 1975;41(5):974-6.
278. Filetti S, Galbiati A, Trimarchi F, Vigneri R. A radioimmunoassay for thyroxine in unextracted serum. *J Nucl Biol Med*. 1975;19(2):86-93.
279. Vigneri R, Filetti S, Galbiati A, Pezzino V, Squatrito S, Polosa P. Effect of dexamethasone on triiodothyronine (T3) response to TSH. *J Nucl Biol Med*. 1975;19(1):29-31.

Partecipazione a Congressi

- Update nella diagnostica e terapia delle patologie tiroidee e paratiroidi - Comando Militare Esercito Emilia Romagna

- Circolo Unificato dell'Esercito. Bologna 17/01/2019;
- Focus Clinico In Endocrinologia Oncologica – AGGIORNAMENTO IN TEMA DI TUMORI NEUROENDOCRINI- Ospedale Santa Maria Goretti – Latina 1/12/2018;
 - Eortc. The Future Of Cancer Therapy- Milano 21-22/11/2018;
 - IFHNOS World Tour – Milano 4-5/11/2018;
 - 17° Congresso Nazionale Ame – Roma 8-11/11/2018;
 - I Nodi Decisionali Nel Carcinoma Differenziato Della Tiroide: Ruolo Del Team Multidisciplinare nella Stadiazione, nel Trattamento e nel Follow-Up - Università Di Brescia 26/10/2018;
 - ESMO – European Society For Medical Oncology – Monaco 19-22/10/2018;
 - 6° Thyroid UpToDate 2018 – Roma 28-29/09/2018;
 - 7° Clinical Update In Endocrinologia E Metabolismo – Centro Congressi San Raffaele 5-6/07/2018;
 - Update Di Terapia Dei Carcinomi Tiroidei Differenziati – Aemilia Hotel – Bologna 8/06/2018;
 - La Gestione Del Carcinoma Tiroideo Alla Luce Delle Nuove Linee Guida Italiane 2018 – Nicolaus Hotel – Bari 10-11/05/2018;
 - I Tumori Della Tiroide - Complesso monumentale dei Santi Marcellino e Festo, Napoli 4/05/2018;
 - ECHNO 2018 – Roma 12/04/2018;
 - ENDO 2018, Endocrine Society – Chicago 16-20/03/2018;
 - 7° Roma Focus Meeting - Roma 9/02/2018;
 - 16° Congresso Nazionale Ame – Roma 9-12/11/2017;
 - Incontri Istituzionali – Boston 30/11-2/12/2017;
 - Sapienza Meets Imperial College – Roma 21/10/2017;
 - Tiroide:Endocrinologo Ed Endocrinochirurgo – Auditorium Camera di Commercio – Verona 14/10/2017;
 - 5°Thyroid UpToDate 2016 – Palazzo Chigi – Ariccia 7/10/2017;
 - 6° Clinical UpToDate In Endocrinologia E Metabolismo – Ospedale San Raffaele, Milano 7/07/2017
 - 39° Congresso Nazionale SIE – Palazzo dei Congressi – Roma 24/06/2017;
 - International Congress Thyroid Cancer Management – Auditorium Centro Didattico Policlinico S. Maria delle Scotte, Siena 9/06/2017;
 - Fare Sistema:Una Opportunita' per la Crescita del Paese – Centro Congressi, Firenze 5/06/2017
 - Invito dell'Ambasciatore di Danimarca presso L'Unione Europea – Bruxelles 18/05/2017;
 - Giornate Romane Di Medicina Clinica – Roma 4-5/05/2017;
 - New Frontiers In Cardiopulmonary And Metabolic Medicine – Crowne Plaza, Roma 24/02/2017;
 - Convegno S.I.F.O. Facciamo Quadrato per la Salute di Tutti – MiCo Milano 3/12/2016;
 - 33° Congresso Nazionale SIMG – Palazzo dei Congressi – Firenze 24-25/11/2016;
 - 3° Congresso Nazionale Club SIE Endocrinologia Oncologica – Cavallerizza Reale – Torino 17-18/11/2016;
 - 15° Congresso Nazionale AME – Ergife Palace Hotel – Roma 12/11/2016;
 - XXIX Congresso Nazionale SNAMID: Farmaci e Salute: la Medicina Generale e la Sfida della Complessita' – Villa Carpegna – Roma 12/11/2016;
 - Convegno Prevenzione Alpha Omega – Tavola Rotonda – Hotel Royal Continental – Napoli , 10/10/2016;
 - 4° Thyroid UpToDate – Palazzo Chigi – Ariccia 8/10/2016;
 - XIII Simposio Internazionale dei Docenti – Aula Magna Sapienza – Roma 8/09/2016;
 - 5° Congresso CUEM – Brescia 7-8/07/2016;
 - European Congress Of Endocrinology- Monaco 28-31/05/2016;
 - Incontri Italiani Di Endocrinologia E Metabolismo – Pisa – 19-20/05/2016;
 - I Tumori Della Tiroide – III Giornata – Centro Congressi Federico II – Napoli 6/05/2016;
 - Corso Scuola Di Endocrinochirurgia 2016 – Policlinico Gemelli – Roma 18/04/2016;
 - Convegno "Controversie In Tema Di Diagnosi E Terapia Del Carcinoma Tiroideo Differenziato – Brescia 28-29/04/2016;
 - ENDO 2016 – Boston (USA) 31/03-04/04/2016;
 - 24ème Journee De Cancerologie Endocrinienne et de Medicine Nucleaire – Espace Maurice Tubiana – Parigi 18/03/2016;
 - Convegno "Stati Generali Della Endocrinologia" – Auditorium I Clinica Medica –Roma 25/01/2016;
 - 9° Congresso Associazione Italiana Della Tiroide – Centro Congressi – Udine 3-5/12/2015;
 - Expedia 2015: Experiential Learning Project On Diabetology – Palazzo della Salute – Padova 17-18/11/2015;
 - 10° Corso Multidisciplinare Di Patologia E Citologia Della Tiroide – Policlinico Gemelli – Roma 13-14/11/2015;
 - Giornate Medico Nucleare Milanese: La Tiroide – Istituto Europeo di Oncologia - Milano 7/11/2015;
 - XXVII Congresso Nazionale SNAMID. Il Paziente Complesso. Hotel NH – Roma 25/10/2015;
 - Convegno Thyroid Cancer – Bruxelles 30/10/2015;
 - 11° Simposio Livornese "Hot Topics In Clinical Endocrinology" – Livorno 9-10/10/2015;
 - 4° Clinical Update In Endocrinologia E Metabolismo (CUEM) – Brescia 3/07/2015;

- Simposio "Le Neoplasie Endocrine" – Villa Smeraldi - Bentivoglio (BO) 10-11/07/2015;
- XI Congresso Nazionale Club delle U.E.C. – Castel dell'Ovo – Napoli 4-6/06/2015;
- Congresso Nazionale S.I.O. – Roma 28/05/2015;
- Advisory Board "Accesso alle Cure in Diabetologia: Orientamento attuale" – Fiumicino Aeroporto (Roma) 9/03/2015;
- Convegno "Attualità ed Innovazioni Tecnologiche in Chirurgia della Tiroide" – Roma 11-12/12/2014;
- Convegno "Carcinoma della Tiroide" – Padova 1-2/12/2014;
- Associazione Italiana Tiroide (AIT) – Milano 27-29/11/2014:
- "Il Carcinoma della Tiroide" – Padova 21/11/2014;
- Convegno "EXPEDIA" – Padova 17-18/11/2014;
- XI Simposio Internazionale e dei Docenti Universitari "L'Idea di Università. Investire nella Conoscenza in Europa e per l'Europa" – Roma 3 - 4/10/2014;
- Thyroid Carcinoma 2014 – Roma 12-13/09/2014;
- Aggiornamento in Tema di Carcinoma differenziato della Tiroide – Napoli 3/10/2014;
- Corso pratico in Endocrinologia e Diabetologia – Sala Polo Universitario, Spedali Riuniti – Livorno, 26- 27/09/2014;
- 3° CUEM "La Terapia della Malattie Endocrino-Metaboliche" – Aula Magna Università di Brescia – 3 – 4/07/2014;
- 16° Congress of Endocrinology (ICE/ENDO 2014) – Chicago (USA), 20-25/06/2014;
- 6° Congresso Monotematico Nazionale " Endocrino_SNAMID" - Hotel NH Bologna de la Gare – Bologna 7-8/06/2014;
- Convegno "Towards Personalized Diagnosis and Therapy for Thyroid Cancer" – Hotel San Ranieri – Pisa, 6-7/05/2014;
- "I Tumori della Tiroide. Il Aggiornamento Multidisciplinare" – Aula Magna Partenope C.C. Federico II Napoli, 9/05/2014;
- 6th Skeletal Endocrinology Meeting – Università di Brescia, Brescia 28-29/03/2014;
- 22 ème Journée de Cancérologie endocrine et de Médecine Nucléaire – Gustave Roussy – Villejuif (France), 21/03/2014;
- "Nuove Linee Guida del Carcinoma Differenziato della Tiroide" – Nerola (Roma) – 14-15/03/2014;
- 7° Congresso A.I.E. – Roma, 6/12/2013;
- Convegno "Il Carcinoma Midollare della Tiroide" – Pisa, 22/11/2013;
- Convegno "Italian Barometer Diabetes – Report 2013 – Palazzo Madama – Roma, 20/11/2013;
- Congresso ESMO 2013 – Amsterdam 26-29/09/2013;
- Congresso "Terapia sostitutiva e TSH soppressiva con ormoni tiroidei" – Napoli, 4/10/2013;
- VIII Congresso Nazionale FIMEG "dal mantenimento dello stato di salute alla qualità di vita nell'anziano" – Centro Congressi Casa dell'Aviatore – Roma, 18-20/09/2013;
- 2nd World Congress on Thyroid Cancer – Toronto (Canada), 10-15/07/2013;
- 6th Italian Parameter Diabetes Forum – Monte Porzio Catone, 10/06/2013;
- 10° Simposio Livornese "Hot Topics in Clinical Endocrinology" – 24-25/05/2013;
- Corso di Aggiornamento in Endocrinologia – Mondello Palace Hotel – Palermo, 17/05/2013;
- Convegno "Dai fattori di rischio allo sviluppo di scompenso cardiaco: strategie di prevenzione e trattamento" – Hilton Sorrento Palace – Napoli, 26- 28/04/2013
- 3° Riunione "Advisory Board Deglutec" – Hotel Rome Airport Fiumicino, 14/12/2012;
- 4° Incontro "Terapia del Diabete" – Roma, 4/12/2012;
- Workshop "Insulin Deglutec Results Meeting" – Londra, 15-16/11/2012;
- Vandetanib Advanced Medullary Thyroid Cancer Expert Meeting – Parigi, 16/10/2012;
- 48th EASD Annual Meeting – Berlino, 29/09 – 04/10/2012;
- 82° Annual Meeting of the American Thyroid Association (ATA) – Canada, 19-24/09/2012;
- 36th Annual Meeting of the European Thyroid Association – Pisa, 10-11/09/2012;
- CUEM Clinical Update in Endocrinologia e Metabolismo – Brescia, 5-6/07/2012;
- Congresso ENDO 2012 – Houston (USA), 21-27/06/2012;
- Convegno "Progetto di formazione sul carcinoma della tiroide" – Firenze, 13/06/2012;
- Riunione Italian Barometer – Roma, 5/06/2012;
- Convegno "L'epidemia nell'epidemia: l'anziano diabetico" – Hotel degli Imperatori – Roma, 6/06/2012;
- Convegno "Carcinoma della Tiroide 2012. Nuove Frontiere nella diagnosi e terapia" – NH V. Veneto – Roma, - Congresso Nazionale Società Italiana di Diabetologia (S.I.D.) – Torino, 24-25/05/2012;
- Il Riunione Board di Esperti di Deglutec – Hilton Rome Airport – Fiumicino, 20/03/2012;
- Congresso "I tumori della tiroide: giornata di aggiornamento" – Hotel Royal Continental – Napoli, 23/03/2012;
- Convegno "Endocrinologia & Metabolismo 2012" Verona, 21/22/03/2012;
- EU Advisory Board Meeting – Advanced Medullary Thyroid Cancer: New Paradigms in Treatment – Crown Plaza Airport Hotel, Bruxelles, 17/02/2012;
- Convegno "Basi molecolari per una terapia personalizzata delle neoplasie maligne della tiroide" – Ospedale Policlinico "G.B. Rossi" – Verona, 11/02/2012;

Autorizzo trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196/2003, che il presente curriculum verrà allegato al programma dell'evento formativo e pubblicato nella banca dati presente nel sito <http://ecm.agenas.it>, e a tal fine presto il consenso al trattamento dei dati personali ivi contenuti.

Data, 05/03/2019

Firma

A handwritten signature in black ink, appearing to read 'S. Filetti', written over a horizontal line.